Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections

Costa Rica HPV Vaccine Trial Group

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background. Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. Methods. A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for

Original languageEnglish (US)
Pages (from-to)939-947
Number of pages9
JournalJournal of Infectious Diseases
Volume213
Issue number6
DOIs
StatePublished - Mar 15 2016

Keywords

  • cross-protection
  • HPV vaccine
  • HPV variants

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections'. Together they form a unique fingerprint.

  • Cite this